Clinical Trials

80 enrolled

Gastric Adenocarcinoma

NCT02867956 2026-03-10

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

35 enrolled

Gynecologic

Ovarian Neoplasms

NCT06346392 2026-03-09

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

572 enrolled

Stomach Neoplasms

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT07033819 2026-02-27

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

48 enrolled

Gynecologic

Ovarian Neoplasms

NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

30 enrolled

Advanced Biliary Tract Carcinoma

NCT05027386 2026-02-05

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.

Phase 1/2 Recruiting

125 enrolled

CNS

Neuroblastoma

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 3 Active not recruiting

80 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT07371910 2026-01-28

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

200 enrolled

Breast

Breast Neoplasms

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Phase 2/3 Active not recruiting

580 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT07357532 2026-01-22

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

44 enrolled

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT05198609 2026-01-21

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

214 enrolled

Carcinoma, Hepatocellular

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Phase 3 Recruiting

550 enrolled

Stomach Neoplasms

NCT07314372 2026-01-20

FAD-HCC-001

86 enrolled

Carcinoma, Hepatocellular

NCT07353684 2026-01-20

Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer

49 enrolled

Phase 3 Not yet recruiting

Adebrelimab

NCT07314203 2026-01-02

SOP-XH-IRB

118 enrolled

Stomach Neoplasms

NCT07311408 2025-12-31

SHR-2554

40 enrolled

Phase 3 Active not recruiting

Stomach Neoplasms

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

687 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Hepatocellular

NCT07309419 2025-12-30

Cocktail-001

222 enrolled

Carcinoma, Hepatocellular

NCT05235100 2025-12-11

SPARE-02

30 enrolled

Sarcoma

NCT06576973 2025-12-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

35 enrolled

Esophageal Squamous Cell Carcinoma

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT06925516 2025-11-28

ACADEMY

38 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06281886 2025-11-17

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

170 enrolled

Esophageal Squamous Cell Carcinoma

NCT06349317 2025-09-29

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

33 enrolled

Carcinoma, Hepatocellular

NCT07192848 2025-09-25

Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy

47 enrolled

Carcinoma, Hepatocellular

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

885 enrolled

Stomach Neoplasms

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

276 enrolled

Other neoplasm

Malignant Neoplasms of Digestive Organs

NCT07105748 2025-08-17

TASK-05

45 enrolled

Liver Neoplasms

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3 Recruiting

200 enrolled

Breast

Fludzoparib" and Anti-angiogenic

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

81 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04560127 2025-07-10

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

20 enrolled

EndocrineHead & Neck

Radioactive Iodine-refractory Differentiated Thyroid Cancer

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06893887 2025-07-02

ICT-HCC

Phase NA Recruiting

300 enrolled

Carcinoma, Hepatocellular

NCT07031154 2025-06-22

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

43 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04625803 2025-06-17

Neoadjuvant Therapy for Locally Advanced Colon Cancer

64 enrolled 11 charts

Phase 1/2 Active not recruiting

Colonic Neoplasms

NCT04581473 2025-06-05

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

192 enrolled

Pancreatic Neoplasms, Stomach Neoplasms

NCT06831175 2025-06-03

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

28 enrolled

Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

NCT06429696 2025-05-28

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

40 enrolled

Small Cell Lung Cancer Extensive Stage

NCT04072042 2025-05-14

BIOVAS

Phase 2/3 Active not recruiting

30 enrolled

Sarcoma

NCT04521153 2025-05-11

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

294 enrolled

Carcinoma, Hepatocellular

NCT06483282 2025-04-15

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

38 enrolled

Small Cell Lung Cancer Limited Stage

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

106 enrolled

Advanced Gastric Cancer

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

140 enrolled

Stomach Neoplasms

NCT05512481 2025-03-03

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

60 enrolled

Dermatologic

Melanoma

NCT05192798 2025-02-27

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

128 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04863430 2025-02-21

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Phase 2 Withdrawn

Phase 2/3 Not yet recruiting

Stomach Neoplasms

NCT06796803 2025-02-10

Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

398 enrolled